ArticleStem cell research & therapy2026
Mesenchymal stem cell-derived microvesicles confer protection against rheumatoid arthritis-associated interstitial lung disease.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundRheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a serious condition with few treatment options and a poor outlook. Mesenchymal stem cell-derived microvesicles (MSC-MVs) offer a potential cell-free therapy, but their effectiveness and the role of their miRNA content in RA-ILD are not well understood.
methodsA mouse model of comorbid RA-ILD was created using collagen-induced arthritis and bleomycin-induced pulmonary fibrosis. Mice received high- or low-dose MSC-MVs via tail vein injection. The treatment effectiveness was evaluated by assessing arthritis severity and pulmonary fibrosis through clinical scores, imaging, histopathology, lung function, and lung coefficients. The expression of fibrotic markers in the lungs was measured using immunohistochemistry and Western blotting. Small RNA sequencing of MSCs-MVs was conducted to explore the underlying mechanism.
resultsAdministering MSCs-MVs significantly reduced the severity of arthritis and pulmonary fibrosis. Treated mice had better joint and lung scores, with decreased fibrotic areas and lower levels of fibrotic proteins such as anti-α-smooth muscle actin, collagen I, and fibronectin. Small RNA sequencing revealed that MSC-MVs contain microRNAs (miRNAs) (e.g., miR-148a-3p) that target critical pathways in RA-ILD, such as transforming growth factor-β (TGF-β) and Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling.
conclusionsOur research revealed that MSCs-MVs significantly protect against RA-ILD in a comorbid model. This protective effect is likely facilitated by the transfer of specific miRNAs that modulate essential profibrotic and inflammatory pathways. These results underscore the therapeutic potential of MSC-MVs as an innovative cell-free approach for RA-ILD treatment and identify miRNA-mediated pathway regulation as a pivotal mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.